Principles of antiangiogenic therapy

Cindy H. Chau; William D. Figg

doi:10.1007/978-1-60327-829-4_17

Principles of antiangiogenic therapy

Cindy H. Chau^*, William D. Figg

^*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

1 Scopus citations

Abstract

Angiogenesis is a critical process to both tumor growth and metastasis in prostate cancer. The markers of angiogenesis in prostate cancer have been identified and could potentially provide prognostic information in addition to clinicopathological data and patient outcome. Promising preclinical studies have led to the initiation of phase I/II studies of antiangiogenic therapy in combination with docetaxel-based chemotherapy in patients with castration-resistant prostate cancer. This chapter describes the mechanisms of the angiogenic process, establishes its role in prostate cancer, and discusses the markers of angiogenesis in prostate cancer, in an attempt to provide an overall understanding of the basic principles of antiangiogenic therapy.

Original language	English
Title of host publication	Drug Management of Prostate Cancer
Publisher	Springer New York
Pages	197-205
Number of pages	9
ISBN (Print)	9781603278317
DOIs	https://doi.org/10.1007/978-1-60327-829-4_17
State	Published - 2010
Externally published	Yes

Keywords

Angiogenesis
Angiogenesis inhibitor
Angiogenic switch
Antiangiogenic therapy
Microvessel density

Access to Document

10.1007/978-1-60327-829-4_17

Cite this

@inbook{12545bce010949b2beaa2a253f9df052,

title = "Principles of antiangiogenic therapy",

abstract = "Angiogenesis is a critical process to both tumor growth and metastasis in prostate cancer. The markers of angiogenesis in prostate cancer have been identified and could potentially provide prognostic information in addition to clinicopathological data and patient outcome. Promising preclinical studies have led to the initiation of phase I/II studies of antiangiogenic therapy in combination with docetaxel-based chemotherapy in patients with castration-resistant prostate cancer. This chapter describes the mechanisms of the angiogenic process, establishes its role in prostate cancer, and discusses the markers of angiogenesis in prostate cancer, in an attempt to provide an overall understanding of the basic principles of antiangiogenic therapy.",

keywords = "Angiogenesis, Angiogenesis inhibitor, Angiogenic switch, Antiangiogenic therapy, Microvessel density",

author = "Chau, {Cindy H.} and Figg, {William D.}",

year = "2010",

doi = "10.1007/978-1-60327-829-4_17",

language = "English",

isbn = "9781603278317",

pages = "197--205",

booktitle = "Drug Management of Prostate Cancer",

publisher = "Springer New York",

}

TY - CHAP

T1 - Principles of antiangiogenic therapy

AU - Chau, Cindy H.

AU - Figg, William D.

PY - 2010

Y1 - 2010

N2 - Angiogenesis is a critical process to both tumor growth and metastasis in prostate cancer. The markers of angiogenesis in prostate cancer have been identified and could potentially provide prognostic information in addition to clinicopathological data and patient outcome. Promising preclinical studies have led to the initiation of phase I/II studies of antiangiogenic therapy in combination with docetaxel-based chemotherapy in patients with castration-resistant prostate cancer. This chapter describes the mechanisms of the angiogenic process, establishes its role in prostate cancer, and discusses the markers of angiogenesis in prostate cancer, in an attempt to provide an overall understanding of the basic principles of antiangiogenic therapy.

AB - Angiogenesis is a critical process to both tumor growth and metastasis in prostate cancer. The markers of angiogenesis in prostate cancer have been identified and could potentially provide prognostic information in addition to clinicopathological data and patient outcome. Promising preclinical studies have led to the initiation of phase I/II studies of antiangiogenic therapy in combination with docetaxel-based chemotherapy in patients with castration-resistant prostate cancer. This chapter describes the mechanisms of the angiogenic process, establishes its role in prostate cancer, and discusses the markers of angiogenesis in prostate cancer, in an attempt to provide an overall understanding of the basic principles of antiangiogenic therapy.

KW - Angiogenesis

KW - Angiogenesis inhibitor

KW - Angiogenic switch

KW - Antiangiogenic therapy

KW - Microvessel density

UR - http://www.scopus.com/inward/record.url?scp=80054989625&partnerID=8YFLogxK

U2 - 10.1007/978-1-60327-829-4_17

DO - 10.1007/978-1-60327-829-4_17

M3 - Chapter

AN - SCOPUS:80054989625

SN - 9781603278317

SP - 197

EP - 205

BT - Drug Management of Prostate Cancer

PB - Springer New York

ER -

Principles of antiangiogenic therapy

Abstract

Keywords

Access to Document

Fingerprint

Cite this